Mycro 3

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mycro 3  纯度: 99.21%

Mycro 3 是一种有效的选择 Myc-Max 二聚化抑制剂。Mycro 3 可用于胰腺癌的研究。

Mycro 3

Mycro 3 Chemical Structure

CAS No. : 944547-46-0

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥2086 In-stock
2 mg ￥1200 In-stock
5 mg ￥1800 In-stock
10 mg ￥2950 In-stock
25 mg ￥6100 In-stock
50 mg ￥11000 In-stock
100 mg 询价

* Please select Quantity before adding items.

Mycro 3 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Anti-Cancer Compound Library
  • Autophagy Compound Library
  • Glutamine Metabolism Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Transcription Factor Targeted Library
  • Targeted Diversity Library

生物活性

Mycro 3 is a potent and selective inhibitor of Myc-associated factor X (MAX) dimerization. Mycro 3 also inhibit DNA binding of c-Myc[1]. Mycro 3 could be used for the research of pancreatic cancer[2].

IC50 & Target

Myc-MAX dimerization[1]
体外研究
(In Vitro)

Mycro 3 is a potent and selective c-Myc inhibitor in whole cell assays, with weak inhibitory activity against Activator protein 1 (AP-1). Mycro 3 has a superior specificity profile to its predecessors. Mycro 3 inhibits the interaction between c-Myc and Max. Mycro 3 has high selectivity and inhibits c-Myc/Max dimerization and conjugation with DNA[1]. Mycro 3 exhibits an excellent specificity with IC50s of 0.25 and 9.0 µM for cells with intact Myc alleles and Myc-null cells, respectively[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Mycro 3 (100 mg/kg; oral administration; daily for two months) induces marked shrinkage of pancreatic ductal adenocarcinoma (PDA), increases cancer cell apoptosis, and reduces cell proliferation. Tumor growth is also drastically attenuated in Mycro 3-treated NOD/SCID mice carrying orthotopic or heterotopic xenografts of human pancreatic cancer cells[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Moribund Pdx1-cre/KRAS* mice bearing pancreatic ductal adenocarcinoma (PDA)[2]
Dosage: 100 mg/kg
Administration: Oral administration; daily for two months
Result: Increased survival time.
Mycro 3 administration was discontinued after two months, the mouse survived for an additional month.

分子量

526.88

Formula

C24H17ClF2N6O4
CAS 号

944547-46-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (189.80 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8980 mL 9.4898 mL 18.9797 mL
5 mM 0.3796 mL 1.8980 mL 3.7959 mL
10 mM 0.1898 mL 0.9490 mL 1.8980 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: 2.5 mg/mL (4.74 mM); Clear solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (4.74 mM) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Chen BJ, et al. Small molecules targeting c-Myc oncogene: promising anti-cancer therapeutics. Int J Biol Sci. 2014 Sep 13;10(10):1084-96.

    [2]. Dimitris Stellas, et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst. 2014 Oct 11;106(12):dju320.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务